MAPT and Alzheimer disease: Furthermore, in a cohort of individuals at risk for an autosomal dominant AD mutation, substantial differences in the carrier and noncarrier levels of CSF and plasma Aβ42 and CSF T-tau were detected at 10, 15, and 15 years before their expected age of symptom onset based on their family history [129], indicating their efficacy as earlier biomarkers of AD onset.